Wednesday, January 22, 2025

Bill Gates’ New Bioterror Project Exposed

 From The Vigilant Fox:

Gates revealed to the Wall Street Journal that he had a three-hour conversation with Trump about “global health,” saying he was “frankly impressed.” What Gates isn’t telling you is that he has been funding risky research projects, including a $9.5 million effort at the University of Wisconsin-Madison to study how bird flu viruses (H5N1) might evolve to infect humans.

According to epidemiologist Nicolas Hulscher, MPH, this work could actually make bird flu more transmissible to humans and “qualifies as bioterrorist activity.”

“And also recently, the Russian Ministry of Defense gave a briefing, and in the briefing, they laid out who is funding these illicit African Biolabs run by the US Military. It’s none other than the Bill and Melinda Gates Foundation and even the Clinton Foundation,” Hulscher revealed.

“So these guys are funding this extremely dangerous research. It’s risking millions of lives,” he warned.

Bill Gates has also explicitly referred to India as his “laboratory” for testing experimental drugs. Such statements raise serious ethical questions about the billionaire’s intentions, especially when he openly expresses a desire to reduce the world’s population.

Adding fuel to the fire, the U.S. Department of Health and Human Services (HHS) recently announced an investment of nearly $600 million in Moderna’s bird flu vaccine development. As journalist Maria Zeee (@zeee_media) pointed out, “Someone is expecting a return on that investment.”

“Why is a man that funds bioterrorist activities, speaking bioterrorist-like activities, rather, speaking with the president about public health?” Hulscher asked.

“He should not be allowed to meet with the President. In my opinion, he should actually be behind bars.”

Meanwhile, more damning evidence continues to mount against the COVID-19 injections.

Nicolas Hulscher, MPH lays out the evidence, demonstrating why these shots should be pulled from the market. (Read more.)
Share

No comments: